Literature DB >> 9066035

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

G W Lawrence1, A Saul, A J Giddy, R Kemp, D Pye.   

Abstract

Seppic MONTANIDE ISA 720 is a metabolizable oil adjuvant that has given good results in animals with recombinant malarial antigens. Twelve human volunteers were given increasing intramuscular doses of MONTANIDE ISA 720, ranging from 0.6 to 1.8 ml. The adjuvant was well tolerated with only minor local effects, including tenderness, local swelling and discomfort on use. MONTANIDE ISA 720 may prove to be an acceptable and effective adjuvant for use in people.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9066035     DOI： 10.1016/s0264-410x(96)00150-8

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  22 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 2.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

3.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-07-19       Impact factor: 3.641

5.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

6.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

7.  Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.

Authors:  Leoneide Érica Maduro Bouillet; Mariana Oliveira Dias; Natália Alves Dorigo; Andrew Douglas Moura; Bruce Russell; Francois Nosten; Laurent Renia; Erika Martins Braga; Ricardo Tostes Gazzinelli; Maurício M Rodrigues; Irene S Soares; Oscar Bruna-Romero
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

8.  Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.

Authors:  Daming Zhu; Holly McClellan; Weili Dai; Elizabeth Gebregeorgis; Mary Anne Kidwell; Joan Aebig; Kelly M Rausch; Laura B Martin; Ruth D Ellis; Louis Miller; Yimin Wu
Journal:  Vaccine       Date:  2011-04-08       Impact factor: 3.641

9.  Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Authors:  Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller
Journal:  Vaccine       Date:  2010-01-04       Impact factor: 3.641

10.  Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Authors:  Meta Roestenberg; Ed Remarque; Erik de Jonge; Rob Hermsen; Hildur Blythman; Odile Leroy; Egeruan Imoukhuede; Soren Jepsen; Opokua Ofori-Anyinam; Bart Faber; Clemens H M Kocken; Miranda Arnold; Vanessa Walraven; Karina Teelen; Will Roeffen; Quirijn de Mast; W Ripley Ballou; Joe Cohen; Marie Claude Dubois; Stéphane Ascarateil; Andre van der Ven; Alan Thomas; Robert Sauerwein
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.